Neurodegenerative Diseases: Pathogenesis and Preclinical Models for Translational Drug Discovery

Area of Science:

• Toxicologic Pathology
• Neuroscience
• Immunology

Background:

• Neurodegenerative diseases pose significant challenges in understanding pathogenesis and developing treatments.
• Current research focuses on advanced in vitro and in vivo models to study complex neurological conditions.
• The European Society of Toxicologic Pathology (ESTP) Congress highlighted recent advancements in this field.

Purpose of the Study:

• To review the latest research on in vitro and in vivo models for neurodegenerative diseases.
• To discuss the application of these models in studying dementia, immune-mediated, and neuromuscular disorders.
• To explore novel therapeutic strategies, including cannabinoid-based options, for neurodegenerative conditions.

Main Methods:

• Overview of animal models for dementia research.
• Investigation of immunological self-tolerance in autoimmune neurodegenerative diseases.
• Application of in vitro models for studying neuromuscular diseases like amyotrophic lateral sclerosis.
• Examination of cannabinoid-based therapeutic approaches.

Main Results:

• Animal models are crucial for understanding dementia pathogenesis and drug development.
• Immunological aspects of autoimmune neurodegenerative diseases (e.g., multiple sclerosis, Guillain-Barré syndrome) were explored.
• In vitro models show utility in studying neuromuscular diseases (e.g., amyotrophic lateral sclerosis).
• Cannabinoid-based therapies demonstrate potential for neuroprotection and neurorepair.

Conclusions:

• The session provided valuable insights into current research and advancements in neurodegenerative disease modeling.
• Progress in modeling offers promising directions for improved therapeutic strategies.
• Further research into novel therapeutic options like cannabinoids is warranted.